182 related articles for article (PubMed ID: 8878127)
1. Quantitative salivary gland scintigraphy in the diagnosis of parenchymal damage after treatment with radioiodine.
Bohuslavizki KH; Brenner W; Lassmann S; Tinnemeyer S; Tönshoff G; Sippel C; Wolf H; Clausen M; Henze E
Nucl Med Commun; 1996 Aug; 17(8):681-6. PubMed ID: 8878127
[TBL] [Abstract][Full Text] [Related]
2. [Quantitative salivary gland scintigraphy--a recommended examination prior to and after radioiodine therapy].
Bohuslavizki KH; Brenner W; Lassmann S; Tinnemeyer S; Kalina S; Clausen M; Henze E
Nuklearmedizin; 1997 Apr; 36(3):103-9. PubMed ID: 9162904
[TBL] [Abstract][Full Text] [Related]
3. Quantitative evaluation of salivary gland dysfunction after radioiodine therapy using salivary gland scintigraphy.
Raza H; Khan AU; Hameed A; Khan A
Nucl Med Commun; 2006 Jun; 27(6):495-9. PubMed ID: 16710103
[TBL] [Abstract][Full Text] [Related]
4. Radioprotection of salivary glands by amifostine in high-dose radioiodine treatment. Results of a double-blinded, placebo-controlled study in patients with differentiated thyroid cancer.
Bohuslavizki KH; Klutmann S; Brenner W; Kröger S; Buchert R; Bleckmann C; Mester J; Henze E; Clausen M
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():6-12. PubMed ID: 10584133
[TBL] [Abstract][Full Text] [Related]
5. Radioprotection of salivary glands by amifostine in high-dose radioiodine therapy.
Bohuslavizki KH; Brenner W; Klutmann S; Hübner RH; Lassmann S; Feyerabend B; Lüttges J; Tinnemeyer S; Clausen M; Henze E
J Nucl Med; 1998 Jul; 39(7):1237-42. PubMed ID: 9669401
[TBL] [Abstract][Full Text] [Related]
6. Salivary gland protection by amifostine in high-dose radioiodine therapy of differentiated thyroid cancer.
Bohuslavizki KH; Klutmann S; Bleckmann C; Brenner W; Lassmann S; Mester J; Henze E; Clausen M
Strahlenther Onkol; 1999 Feb; 175(2):57-61. PubMed ID: 10065139
[TBL] [Abstract][Full Text] [Related]
7. Systematic evaluation of salivary gland damage following I-131 therapy in differentiated thyroid cancer patients by quantitative scintigraphy and clinical follow-up.
Wu JQ; Feng HJ; Ouyang W; Sun YG; Chen P; Wang J; Xian JL; Huang LH
Nucl Med Commun; 2015 Aug; 36(8):819-26. PubMed ID: 25932534
[TBL] [Abstract][Full Text] [Related]
8. Quantification of salivary gland function in thyroid cancer patients treated with radioiodine.
Malpani BL; Samuel AM; Ray S
Int J Radiat Oncol Biol Phys; 1996 Jun; 35(3):535-40. PubMed ID: 8655377
[TBL] [Abstract][Full Text] [Related]
9. Salivary gland protection by amifostine in high-dose radioiodine treatment: results of a double-blind placebo-controlled study.
Bohuslavizki KH; Klutmann S; Brenner W; Mester J; Henze E; Clausen M
J Clin Oncol; 1998 Nov; 16(11):3542-9. PubMed ID: 9817273
[TBL] [Abstract][Full Text] [Related]
10. Scintigraphic evaluation of salivary gland dysfunction in patients with thyroid cancer after radioiodine treatment.
Caglar M; Tuncel M; Alpar R
Clin Nucl Med; 2002 Nov; 27(11):767-71. PubMed ID: 12394122
[TBL] [Abstract][Full Text] [Related]
11. Salivary gland protection by S-2-(3-aminopropylamino)-ethylphosphorothioic acid (amifostine) in high-dose radioiodine treatment: results obtained in a rabbit animal model and in a double-blind multi-arm trial.
Bohuslavizki KH; Klutmann S; Jenicke L; Kröger S; Buchert R; Mester J; Clausen M
Cancer Biother Radiopharm; 1999 Oct; 14(5):337-47. PubMed ID: 10850318
[TBL] [Abstract][Full Text] [Related]
12. Iodine kinetics and dosimetry in the salivary glands during repeated courses of radioiodine therapy for thyroid cancer.
Liu B; Huang R; Kuang A; Zhao Z; Zeng Y; Wang J; Tian R
Med Phys; 2011 Oct; 38(10):5412-9. PubMed ID: 21992360
[TBL] [Abstract][Full Text] [Related]
13. Salivary gland scintigraphy after radioiodine therapy.
Malpani BL; Samuel AM; Jaiswar RK
Nucl Med Commun; 1998 Feb; 19(2):183-4. PubMed ID: 9548203
[No Abstract] [Full Text] [Related]
14. Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy.
Solans R; Bosch JA; Galofré P; Porta F; Roselló J; Selva-O'Callagan A; Vilardell M
J Nucl Med; 2001 May; 42(5):738-43. PubMed ID: 11337569
[TBL] [Abstract][Full Text] [Related]
15. [Salivary gland damage after 131I therapy in patients with differentiated thyroid cancer. Preliminary report].
Macioszek A; Baczyk M; Kopeć T; Sowiński J
Endokrynol Pol; 2008; 59(5):403-10. PubMed ID: 18979451
[TBL] [Abstract][Full Text] [Related]
16. Radioprotection of salivary glands by S-2-(3-aminopropylamino)-ethylphosphorothioic (amifostine) obtained in a rabbit animal model.
Bohuslavizki KH; Klutmann S; Jenicke L; Brenner W; Feyerabend B; Henze E; Clausen M
Int J Radiat Oncol Biol Phys; 1999 Aug; 45(1):181-6. PubMed ID: 10477022
[TBL] [Abstract][Full Text] [Related]
17. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer?
Nakada K; Ishibashi T; Takei T; Hirata K; Shinohara K; Katoh S; Zhao S; Tamaki N; Noguchi Y; Noguchi S
J Nucl Med; 2005 Feb; 46(2):261-6. PubMed ID: 15695785
[TBL] [Abstract][Full Text] [Related]
18. Relationship between cumulative radiation dose and salivary gland uptake associated with radioiodine therapy of thyroid cancer.
Jentzen W; Schneider E; Freudenberg L; Eising EG; Görges R; Müller SP; Brandau W; Bockisch A
Nucl Med Commun; 2006 Aug; 27(8):669-76. PubMed ID: 16829767
[TBL] [Abstract][Full Text] [Related]
19. Salivary gland function 5 years after radioactive iodine ablation in patients with differentiated thyroid cancer: direct comparison of pre- and postablation scintigraphies and their relation to xerostomia symptoms.
Jeong SY; Kim HW; Lee SW; Ahn BC; Lee J
Thyroid; 2013 May; 23(5):609-16. PubMed ID: 23153322
[TBL] [Abstract][Full Text] [Related]
20. Radioiodine-Induced Salivary Gland Damage Detected by Ultrasonography in Patients Treated for Papillary Thyroid Cancer: Radioactive Iodine Activity and Risk.
Horvath E; Skoknic V; Majlis S; Tala H; Silva C; Castillo E; Whittle C; Niedmann JP; González P
Thyroid; 2020 Nov; 30(11):1646-1655. PubMed ID: 32370663
[No Abstract] [Full Text] [Related]
[Next] [New Search]
